The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles

GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study

(2020) J Haas et al.   HUMAN REPRODUCTION

Relugolix: First Global Approval

(2019) Anthony Markham   DRUGS

Premature progesterone rise in ART-cycles

(2018) Barbara Lawrenz et al.   Reproductive Biology

Decrease in preovulatory serum estradiol is a valuable marker for predicting premature ovulation in natural/unstimulated in vitro fertilization cycle

(2018) Xuefeng Lu et al.   Journal of Ovarian Research

Evidence-based approach to unexplained infertility: a systematic review

(2016) Deidre D. Gunn et al.   FERTILITY AND STERILITY

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males

(2015) David B. MacLean et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM